Could cancer vaccines be next? New treatment cuts melanoma risk by nearly 50%

A new personalized mRNA cancer therapy, intismeran autogene, combined with KEYTRUDA, reduced melanoma recurrence or death risk by 49% over five years in a phase 2b study. The treatment, developed by Merck and Moderna, showed sustained benefits and a manageable safety profile in high-risk melanoma patients. It is now in phase 3 trials.